Filter Results:
(227)
Show Results For
- All HBS Web
(227)
- People (1)
- News (75)
- Research (130)
- Events (1)
- Multimedia (2)
- Faculty Publications (75)
Show Results For
- All HBS Web
(227)
- People (1)
- News (75)
- Research (130)
- Events (1)
- Multimedia (2)
- Faculty Publications (75)
Page 1 of 227
Results →
- September 1962
- Case
Molecular Compounds Corp. (Abridged)
Vandell, Robert F., and William W. Sihler. "Molecular Compounds Corp. (Abridged)." Harvard Business School Case 210-088, September 1962.
- October 2019
- Supplement
Granite Equity Compounding Returns Calculations
By: Victoria Ivashina and Terrence Shu
- 2007
- Report
Compounding Impact: Mission Investing by U.S. Foundations
By: Mark R. Kramer and Sarah E. Cooch
If foundations are to achieve their lofty ambitions for social impact, they must find creative ways to use every resource they possess. Enter mission investing (now more popularly called impact investing), a practice of using financial investments as tools to achieve a... View Details
Keywords: Foundations; Mission Investing; Impact Investing; Organizations; Mission and Purpose; Investment
Kramer, Mark R., and Sarah E. Cooch. "Compounding Impact: Mission Investing by U.S. Foundations." Report, FSG, March 2007.
- April 2017
- Case
Imprimis (A)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The (A) case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in... View Details
Keywords: Strategy; Healthcare; Drug Compounding; Pharmaceuticals; Compounding; Drug Development; Decision-making; Mark Baum; Imprimis; Small Business; Decisions; Cost vs Benefits; Business Strategy; Business Model; Decision Choices and Conditions; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (A)." Harvard Business School Case 717-426, April 2017.
- April 2017
- Supplement
Imprimis (B)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details
Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (B)." Harvard Business School Supplement 717-496, April 2017.
- 13 Apr 2020
- Research & Ideas
Small Businesses Are Worse Off Than We Thought
If the COVID-19 crisis lasts four months, 65 percent of small retailers say there’s a good chance they’ll be forced to close permanently by the end of the year. Among restaurants and bars, 70 percent expect to go out of business if social-distancing orders last into... View Details
- June 2001
- Case
Bond Math
This case presents four exercises that teach compounding interest and valuing bonds. View Details
Pulvino, Todd C., and Peter Tufano. "Bond Math." Harvard Business School Case 201-101, June 2001.
- July 1997
- Background Note
Basic Capital Investment Analysis
By: William J. Bruns Jr.
Discusses the net present value and internal rate of return methods for analyzing capital investments. Assumes prior knowledge of compound interest and present value methods. View Details
Bruns, William J., Jr. "Basic Capital Investment Analysis." Harvard Business School Background Note 198-004, July 1997.
- April 2017
- Supplement
Imprimis (D)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also... View Details
Keywords: Decision Choices and Conditions; Growth and Development Strategy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (D)." Harvard Business School Supplement 717-498, April 2017.
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- October 1991 (Revised September 2004)
- Case
Buying Time
By: William J. Bruns Jr. and Susan Harmeling
A self-contained explanation and simple practice examples to introduce students to the concepts of compound interest, present value loans, bonds, and leases. Necessary present value tables are included. The study questions provide simple exercises to enhance student... View Details
Bruns, William J., Jr., and Susan Harmeling. "Buying Time." Harvard Business School Case 192-045, October 1991. (Revised September 2004.)
- 17 Jul 2012
- News
Zuck's Sweet ReFi: Is This Why It's Called the One Percent?
- 29 Apr 2012
- News
Foreign CEOs face challenges in Japan
- October 2023
- Article
Laboratory Safety and Research Productivity
By: Alberto Galasso, Hong Luo and Brooklynn Zhu
Are laboratory safety practices a tax on scientific productivity? We examine this question by exploiting the substantial increase in safety regulations at the University of California following the shocking accidental death of a research assistant in 2008.... View Details
Keywords: Economics Of Science; Risk Perception; Safety Regulations; Governing Rules, Regulations, and Reforms; Working Conditions; Safety; Performance Productivity
Galasso, Alberto, Hong Luo, and Brooklynn Zhu. "Laboratory Safety and Research Productivity." Art. 104827. Research Policy 52, no. 8 (October 2023).
- 05 Oct 2022
- Video
About Face: Pivoting from Science to Entrepreneurship
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- August 2001
- Technical Note
Technical Note on Expectations
Reviews the mathematics of expectations embedded in a company's current stock price and the related (whole) enterprise value. Begins by showing how the current stock price can be compounded forward to arrive at an expectation one or more years in the future. Describes... View Details
Baldwin, Carliss Y. "Technical Note on Expectations." Harvard Business School Technical Note 902-055, August 2001.
- March 2023
- Case
On
By: Ramon Casadesus-Masanell, Karolin Frankenberger and Sascha Mader
Founded in 2010, in just one decade, the Swiss company On had established itself as a main player in global sports footwear and apparel. Based on an unconventional strategy which one of the founders labeled as “obsessively distinct,” On grew its sales with a compound... View Details